secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2022-03-17T23:59:59+00:00
Accession:  0001193125-22-077804
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Oncology reports Q4 2021 net loss of $34.4M; cash $430.9M through 2024
-------------------------------------------------------------------------------

- Net loss $34.4M in Q4 2021 vs $18.4M in Q3 2021; FY 2021 net loss $67.5M vs $59.5M in FY 2020.
- Cash and investments $430.9M as of Dec 31, 2021, expected to fund operations through 2024.
- CLN-081 Phase 1/2a data: 39% confirmed PR at 100mg BID; median DOR >15 months, PFS 12 months.
- CLN-081 received FDA Breakthrough Therapy Designation in Jan 2022; regulatory update expected Q1 2022.
- CLN-049 and CLN-619 first-in-human dosing initiated Dec 2021; initial data expected by mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312522077804/0001193125-22-077804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312522077804/d331653d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-077804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer